Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar;64(6):e1901018.
doi: 10.1002/mnfr.201901018. Epub 2020 Feb 17.

The Effect of Lactobacillus fermentum ME-3 Treatment on Glycation and Diabetes Complications

Axel Guilbaud  1   2   3 , Michael Howsam  1   3 , Céline Niquet-Léridon  3   4 , Florian Delguste  1 , Marc Fremont  2 , Sophie Lestavel  5 , Patrice Maboudou  6 , Anne Garat  7 , Susanna Schraen  6 , Brigitte Onraed  6 , Benoît Foligné  8 , Éric Boulanger  1   3 , Frédéric J Tessier  1   3
Affiliations

The Effect of Lactobacillus fermentum ME-3 Treatment on Glycation and Diabetes Complications

Axel Guilbaud et al. Mol Nutr Food Res. 2020 Mar.

Abstract

Scope: Type 2 diabetes (T2D) induces organ damage associated with glycation, among other metabolic pathways. While therapeutic strategies have been tested to reduce the formation and impact of glycation products, results remain equivocal. Anti-diabetic therapies using probiotics have been proposed, but their effect upon glycation has not been reported. Here, the effects of the bacterial strain Lactobacillus fermentum ME-3 on glycation and T2D-related complications in a mouse model of T2D are investigated.

Methods & results: Wild-type LepRdb/+ and diabetic LepRdb/db littermates receive a daily gavage of either water or the probiotic ME-3 strain (1010 CFU). Glycation markers, fructoselysine-derived furosine (FL-furosine) and carboxymethyllysine (CML), are quantified in four major organs and plasma using stable-isotope dilution LC-MS/MS. After 12 weeks of ME-3 treatment, diabetic mice gain less weight and exhibit an apparently improved glucose tolerance. The ME-3 treatment reduces median renal levels of FL-furosine in both genotypes by 12-15%, and renal and pulmonary free-CML in diabetic mice by 30% and 18%, respectively. Attenuated hepatic steatosis and an improved plasma lipid profile are also observed with treatment in both genotypes, while the gut microbiota profile is unchanged.

Conclusion: L. fermentum ME-3 has therapeutic potential for reducing the formation/accumulation of some glycation products in kidneys and attenuating some common diabetes-related complications.

Keywords: carboxymethyllysine; diabetes; furosine; glycation; probiotics.

PubMed Disclaimer

References

    1. R. Singh, A. Barden, T. Mori, L. Beilin, Diabetologia 2001, 44, 129.
    1. F. J. Tessier, Pathol. Biol. 2010, 58, 214.
    1. J. M. Forbes, L. T. Yee, V. Thallas, M. Lassila, R. Candido, K. A. Jandeleit-Dahm, M. C. Thomas, W. C. Burns, E. K. Deemer, S. R. Thorpe, M. E. Cooper, T. J. Allen, Diabetes 2004, 53, 1813.
    1. S. Stegen, B. Stegen, G. Aldini, A. Altomare, L. Cannizzaro, M. Orioli, S. Gerlo, L. Deldicque, M. Ramaekers, P. Hespel, W. Derave, Appl. Physiol. Nutr. Metab. 2015, 40, 868.
    1. N. L. Alderson, M. E. Chachich, N. N. Youssef, R. J. Beattie, M. Nachtigal, S. R. Thorpe, J. W. Baynes, Kidney Int. 2003, 63, 2123.

Publication types

MeSH terms